FDA May Speed Drug Ad Review For Fee
Fees from the deal would help pay for the new staff needed to review the industry’s TV ads, the Wall Street Journal reported.
The FDA's Division of Drug Marketing, Advertising and Communications was recently restructured to address the ever-increasing workload of reviewing direct-to-consumer advertising materials.
In early September, the original DTC review...
To view the full article, register now.